Hemogenyx Pharmaceuticals

(HEMO)
Sector: Pharmaceuticals & Biotechnology
168.75p
1.50p 0.90
Last updated: 16:45:18

Company News Headlines

Date Time Headline Source
03/04/2025 07:00 FDA Annual Report RNS
31/03/2025 07:00 Total Voting Rights RNS
24/03/2025 07:00 First Patient Safety RNS
17/03/2025 07:00 Recruitment of Second Patient for Clinical Trials RNS
13/03/2025 15:10 Conversion of convertible loan notes RNS
11/03/2025 07:00 Institutional investment RNS
24/02/2025 07:00 First-in-Human Treatment with HG-CT-1 RNS
19/02/2025 16:50 Issue of convertible loan notes RNS
31/01/2025 09:35 Total Voting Rights RNS
08/01/2025 07:00 Placing to raise £340,000 RNS
02/01/2025 07:00 Change of Company Secretary and Registered Office RNS
31/12/2024 07:00 Total Voting Rights RNS
30/12/2024 07:00 Opening of First Clinical Site RNS
19/12/2024 07:00 Ultrafast CAR-T Manufacturing RNS
10/12/2024 16:10 Admission of New Ordinary Shares and New ISIN RNS
09/12/2024 13:30 Result of Extraordinary General Meeting RNS
09/12/2024 07:00 Site Initiation Visit Completed RNS
06/12/2024 07:00 CBR Macrophage Delivery Update RNS
29/11/2024 07:00 Total Voting Rights RNS
22/11/2024 12:49 Notice of Extraordinary General Meeting RNS
22/11/2024 07:00 IRB Approval for Phase I Clinical Trial RNS
11/11/2024 07:00 Institutional Investment RNS
30/10/2024 07:00 Schedule for Phase I Clinical Trial Opening RNS
02/10/2024 11:19 Strategic Investment from Prevail Partners, LLC RNS
27/09/2024 07:00 Half-year Report RNS
09/09/2024 07:00 FLT3 Assay Ready for Phase I Trials at MD Anderson RNS
02/09/2024 07:00 CDX Development Update RNS
28/08/2024 07:00 Presentation at CBD S&T Conference RNS
27/06/2024 16:39 Result of Annual General Meeting RNS
17/06/2024 07:00 Operations Update RNS
03/06/2024 07:00 Posting of Annual Report & Notice of AGM RNS
25/04/2024 07:00 Final Results RNS
28/03/2024 07:00 Total Voting Rights RNS
29/02/2024 07:00 Placing to Raise US$4.2 million RNS
16/02/2024 07:00 CBR Brain Delivery RNS
14/02/2024 07:00 CBR Intranasal Delivery RNS
09/02/2024 07:00 FDA Consents to Phase I Trials of HEMO-CAR-T RNS
02/02/2024 07:00 Approval and Issuance of U.S. Conditioning Patent RNS
16/01/2024 07:00 Submission of Complete Response to Clinical Hold RNS
08/01/2024 07:00 HEMO-CAR-T Process Qualification Run Completed RNS
28/11/2023 12:19 Placing to Raise £534,375 RNS
27/11/2023 07:00 CBR Expanded to Treatment of Cancer RNS
15/11/2023 07:00 Lentivirus Re-manufacturing Completed RNS
31/10/2023 07:00 Total Voting Rights RNS
28/09/2023 12:28 Half-year Report RNS
18/09/2023 07:00 Strategic Investment from Prevail Partners, LLC RNS
14/09/2023 07:00 Clinical Hold Lift Plan is accepted by FDA RNS
10/07/2023 07:00 Full FDA Review for HEMO-CAR-T IND RNS
30/06/2023 16:07 Result of Annual General Meeting RNS
02/06/2023 14:01 Posting of Annual Report & Notice of AGM RNS